+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Von Willebrand Disease Treatment Market by Disease Type (Acquired VWD, Type 1, Type 2), Treatment (Clot-Stabilizing, Desmopressin, Replacement Therapies), Route of Administration - Forecast 2024-2030

  • PDF Icon

    Report

  • 191 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5715686
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Von Willebrand Disease Treatment Market size was estimated at USD 653.12 million in 2023, USD 718.76 million in 2024, and is expected to grow at a CAGR of 11.30% to reach USD 1,382.12 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Von Willebrand Disease Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Von Willebrand Disease Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Von Willebrand Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Accredo Health Group, Inc., Affinity Biologicals Incorporated, ARUP Laboratories, AstraZeneca PLC, Baxter Healthcare Corporation, Bayer AG, Bio Products Laboratory Ltd., Biogen Inc., Bristol Myers Squibb, CSL Limited, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc, Genentech Inc., Grifols, S.A., Laboratory Corporation of America Holdings, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., Siemens Healthcare GmbH, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Von Willebrand Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Acquired VWD
    • Type 1
    • Type 2
    • Type 3
  • Treatment
    • Clot-Stabilizing
    • Desmopressin
    • Replacement Therapies
  • Route of Administration
    • Injection
    • Oral
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Von Willebrand Disease Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Von Willebrand Disease Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Von Willebrand Disease Treatment Market?
  4. What is the market share of the leading vendors in the Von Willebrand Disease Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Von Willebrand Disease Treatment Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Von Willebrand Disease Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in the number of people suffering from Von Willebrand disease
5.1.1.2. Increase in patient assistance programs and growing healthcare expenditure
5.1.1.3. Government initiatives to increase the efficacy and success rates of innovative treatments
5.1.2. Restraints
5.1.2.1. High cost associated with Von Willebrand disease treatment
5.1.3. Opportunities
5.1.3.1. Increasing number of product approvals for Von Willebrand disease treatment
5.1.3.2. Ongoing development of new treatments and diagnostic tools for Von Willebrand disease treatment
5.1.4. Challenges
5.1.4.1. Lack of awareness related to Von Willebrand disease treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Von Willebrand Disease Treatment Market, by Disease Type
6.1. Introduction
6.2. Acquired VWD
6.3. Type 1
6.4. Type 2
6.5. Type 3
7. Von Willebrand Disease Treatment Market, by Treatment
7.1. Introduction
7.2. Clot-Stabilizing
7.3. Desmopressin
7.4. Replacement Therapies
8. Von Willebrand Disease Treatment Market, by Route of Administration
8.1. Introduction
8.2. Injection
8.3. Oral
9. Americas Von Willebrand Disease Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Von Willebrand Disease Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Von Willebrand Disease Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Accredo Health Group, Inc.
13.1.2. Affinity Biologicals Incorporated
13.1.3. ARUP Laboratories
13.1.4. AstraZeneca PLC
13.1.5. Baxter Healthcare Corporation
13.1.6. Bayer AG
13.1.7. Bio Products Laboratory Ltd.
13.1.8. Biogen Inc.
13.1.9. Bristol Myers Squibb
13.1.10. CSL Limited
13.1.11. F. Hoffmann-La Roche AG
13.1.12. Ferring Pharmaceuticals Inc
13.1.13. Genentech Inc.
13.1.14. Grifols, S.A.
13.1.15. Laboratory Corporation of America Holdings
13.1.16. Novo Nordisk A/S
13.1.17. Octapharma AG
13.1.18. Pfizer Inc.
13.1.19. Sanofi S.A.
13.1.20. Siemens Healthcare GmbH
13.1.21. Sun Pharmaceutical Industries Limited
13.1.22. Takeda Pharmaceutical Company Limited
13.1.23. Thermo Fisher Scientific Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. VON WILLEBRAND DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. VON WILLEBRAND DISEASE TREATMENT MARKET DYNAMICS
FIGURE 7. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 8. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 10. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. VON WILLEBRAND DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. VON WILLEBRAND DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. VON WILLEBRAND DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 6. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACQUIRED VWD, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 11. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLOT-STABILIZING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 15. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 28. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 29. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 31. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 32. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 45. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 48. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 54. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 72. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 82. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 85. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 88. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 91. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 100. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 109. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 110. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 112. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 115. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 136. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. VON WILLEBRAND DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 145. VON WILLEBRAND DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. VON WILLEBRAND DISEASE TREATMENT MARKET LICENSE & PRICING

Companies Mentioned

  • Accredo Health Group, Inc.
  • Affinity Biologicals Incorporated
  • ARUP Laboratories
  • AstraZeneca PLC
  • Baxter Healthcare Corporation
  • Bayer AG
  • Bio Products Laboratory Ltd.
  • Biogen Inc.
  • Bristol Myers Squibb
  • CSL Limited
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals Inc
  • Genentech Inc.
  • Grifols, S.A.
  • Laboratory Corporation of America Holdings
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Siemens Healthcare GmbH
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information